Umbilical cord stem cells for liver failure
Part of Digestive system clinical trials.
This trial tests if infusions of stem cells from donated umbilical cords can help people with a severe type of liver failure caused by hepatitis B. It aims to see if the treatment is safe and can improve liver function.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have liver failure caused by hepatitis B, with high bilirubin levels and abnormal blood clotting.
- You and your partner agree to use birth control during the study and for 6 months after.
- You have no history of allergy to the study drug or beef products.
- You do not have active bleeding, severe brain fog, kidney failure, or cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether stem cells from donated umbilical cords can help people with acute-on-chronic liver failure, a sudden worsening of chronic liver disease. The goal is to see if this treatment improves liver function and survival.
This trial tests whether injecting special stem cells (called mesenchymal stem cells) can help people with a sudden worsening of chronic liver disease (called acute-on-chronic liver failure) who do not have a virus as the cause. It is for patients who are too sick for standard treatment but who cannot get a liver transplant right away.
This early-phase study tests whether stem cells (called mesenchymal stem cells) are safe and can help people with a sudden, severe liver failure. You may qualify if your liver is failing quickly and you are not eligible for a transplant.
This trial looks at how well stem cell (MSC) treatment works for people with severe liver failure caused by hepatitis B. It checks what factors affect the success of the treatment.
This trial tests whether infusing stem cells (from a healthy donor) can help people with sudden liver failure that is not getting better with standard medicines and is not caused by viruses. It aims to improve liver function and possibly avoid the need for a transplant.
This trial studies a combination approach called DPMAS and low-volume plasma exchange for people with hepatitis B–related acute-on-chronic liver failure. If you qualify, the goal is to improve your liver function and reduce serious complications from liver failure.
Hear when a new Acute-On-Chronic Liver Failure trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.